Previous 10 | Next 10 |
PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2023, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2023. Particip...
2023-04-28 05:30:40 ET A committee of the European Medicines Agency (EMA) recommended the approval of Amicus Therapeutics' ( NASDAQ: FOLD ) oral therapy Opfolda (miglustat) in combination with cipaglucosidase alfa to treat glycogen storage disease type 2, or Pompe disease....
European Commission Approval of Opfolda and Commercial Launch of Pombiliti ® + Opfolda ® Anticipated in 3Q 2023 Upon Approval, Pombiliti + Opfolda will be the First Two-Component Therapy in the European Union for the Treatment of Adu...
2023-04-21 17:30:06 ET Gold fell sharply Friday and posted its worst week since February, as hawkish remarks by Federal Reserve officials seemed to raise the likelihood for at least one more interest rate hike. Cleveland Fed President Loretta Mester was the latest to state her suppo...
2023-04-12 16:30:23 ET Gold futures closed Wednesday at their highest in nearly a week, with the dollar declining as signs of cooling inflation added to hopes for a pause in U.S. rate increases. The Consumer Price Index rose by a less than expected 0.1% in March after climbing 0.4% ...
2023-03-27 07:47:09 ET Amicus Therapeutics ( NASDAQ: FOLD ) has received approval from the European Commission for its Pombiliti enzyme replacement therapy. The Commission approved Pombiliti as a long-term enzyme replacement therapy, in combination with miglustat, for adul...
Approved as a Long-Term Enzyme Replacement Therapy in Combination with Miglustat for All Adults Living with Late-Onset Pompe Disease CHMP Opinion for Miglustat, the Oral Enzyme Stabilizer Component of AT-GAA, On-Track for 2Q 2023 PHILADELPHIA, March 27, 2023 (GLOBE NEW...
2023-03-08 13:57:48 ET Summary Amicus ended FY’22 with a growing topline and reassuring outlook from the management. The company seems well-prepared for pre-approval inspection and also seems optimistic about regulatory approval of their AT-GAA this year. The success of...
Amicus Therapeutics. (FOLD) Q4 2022 Earnings Conference Call March 01, 2023, 08:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President, Chief Executive Officer Sébastien Martel - Chief Business Officer J...
The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Amicus Therapeutics, Inc. 2022 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Amicus Therapeutics Inc. Company Name:
FOLD Stock Symbol:
NASDAQ Market:
Amicus Therapeutics Inc. Website:
PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2024, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2024. Par...
2024-07-01 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T. A live audio...